WIRB - AN OPEN-LABEL, MULTIPLE-DOSE, CROSS-OVER STUDY TO EVALUATE: HIV

WIRB - 一项开放标签、多剂量、交叉研究来评估：HIV

• 批准号: 8167327
• 负责人: Steven L. Zeichner
• 金额: $ 0.31万
• 依托单位: CHILDREN'S RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-01-20 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167327
• 关键词: 18 year old; Adherence; Child; Computer Retrieval of Information on Scientific Projects Database; Cross-Over Studies; Dose; Drug Formulations; Drug Kinetics; Funding; Grant; HIV; Institution; Marketing; Nevirapine; Oral; Regimen; Relative (related person); Research; Research Personnel; Resources; Source; Suspension substance; Suspensions; Tablets; Therapeutic; United States National Institutes of Health; Viral; antiretroviral therapy; compliance behavior; improved; open label; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective is to establish the pharmacokinetic profile at steady state of nevirapine XR in children from e3 to 18 years of age. Adherence is a major factor in determining the degree of viral suppression achieved in response to antiretroviral therapy. An extended release formulation of nevirapine may offer a meaningful therapeutic benefit, relative to marketed nevirapine oral suspension and 200 mg BID tablets by facilitating a once daily dosing regimen, thus improving treatment compliance. In addition, nevirapine extended release could demonstrate improved tolerability in comparison with the marketed suspension.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 主要目的是在奈韦拉平XR的稳态状态下建立药代动力学谱 在E3至18岁的儿童中。依从性是确定程度的主要因素 响应抗逆转录病毒疗法而获得的病毒抑制。扩展版本 奈韦拉平的配方可能会提供有意义的治疗益处 Nevirapine口服悬浮液和200 mg竞标片，通过促进每日给药方案， 从而提高了治疗依从性。此外，奈韦拉平的扩展释放可能 与销售的悬架相比，证明可耐受性的提高。